67416-61-9 Usage
in vitro
akba exerted a time- and concentration -dependent cytotoxicity on androgen-independent prostate cancer cells. akba blocked proliferation and elicited apoptosis in the chemoresistant and androgen-independent human pc-3 prostate cancer cells by the release of mitochondrial cytochrome c and dna fragmentation. also, akba concentration-dependently inhibited nf-κb signaling, yet it did not directly affect the nf-κb binding to dna. additionally, akba suppressed inhibitor κb kinase and nf-κb-dependent antiapoptotic gene products in pc-3 cells [1].
in vivo
pc-3 xenotransplanted male nmri/nu-nu mice were injected intraperitoneally at 100 μmol/kg daily for three weeks. akba dampened growth and proliferation of pc-3 xenografts in nude mice and elicited apoptosis. moreover, compared with the control group, akba reduced the tumor volume and the invasiveness of the tumor into the surrounding tissues [1].
references
[1]. syrovets, t., gschwend, j., buchele, b., laumonnier, y., zugmaier, w., genze, f., & simmet, t. inhibition of iκb kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent pc-3 prostate cancer cells in vitro and in vivo. journal of biological chemistry. 2004; 280(7): 6170-6180.
Check Digit Verification of cas no
The CAS Registry Mumber 67416-61-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,7,4,1 and 6 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 67416-61:
(7*6)+(6*7)+(5*4)+(4*1)+(3*6)+(2*6)+(1*1)=139
139 % 10 = 9
So 67416-61-9 is a valid CAS Registry Number.
InChI:InChI=1/C32H48O5/c1-18-9-12-28(4)15-16-30(6)21(25(28)19(18)2)17-22(34)26-29(5)13-11-24(37-20(3)33)32(8,27(35)36)23(29)10-14-31(26,30)7/h17-19,23-26H,9-16H2,1-8H3,(H,35,36)/t18-,19+,23-,24-,25+,26-,28-,29+,30-,31-,32-/m1/s1
67416-61-9Relevant articles and documents
NOVEL SALTS OF BOSWELLIC ACIDS AND SELECTIVELY ENRICHED BOSWELLIC ACIDS AND PROCESSES FOR THE SAME
-
Page/Page column 11-12, (2008/06/13)
The present invention relates to new salts or ion ion-pair complexes obtained by a reaction between boswellic acids or selectively enriched 3-O-acetyl-11-keto-?-boswellic acid (AKBA) or 11-keto-?-boswellic acid (KBA) compounds obtained through a new improved process, and an organic amine, more particularly with glucosamine. These salts or ion pair complexes are useful in nutraceuticals and in food supplements for anti-inflammatory and analgesic treatment of joints and cancer prevention or cancer therapeutic agents. These salts or ion pair complexes could also used in cosmetic or pharmaceutical composition for external body part or organ to treat inflammatory diseases or cancer.
